-DOCSTART- -X- O
Zika -X- _ B-Patient
virus -X- _ I-Patient
( -X- _ I-Patient
ZIKV -X- _ I-Patient
) -X- _ I-Patient
remained -X- _ O
largely -X- _ O
quiescent -X- _ O
for -X- _ O
nearly -X- _ O
six -X- _ O
decades -X- _ O
after -X- _ O
its -X- _ O
first -X- _ O
appearance -X- _ O
in -X- _ O
1947. -X- _ O
ZIKV -X- _ B-Patient
reappeared -X- _ O
after -X- _ O
2007 -X- _ O
, -X- _ O
resulting -X- _ O
in -X- _ O
a -X- _ O
declaration -X- _ O
of -X- _ O
an -X- _ O
international -X- _ O
“public -X- _ O
health -X- _ O
emergency” -X- _ O
in -X- _ O
2016 -X- _ O
by -X- _ O
the -X- _ O
World -X- _ O
Health -X- _ O
Organization -X- _ O
( -X- _ O
WHO -X- _ O
) -X- _ O
. -X- _ O
Until -X- _ O
this -X- _ O
time -X- _ O
, -X- _ O
ZIKV -X- _ O
was -X- _ O
considered -X- _ O
to -X- _ O
induce -X- _ O
only -X- _ O
mild -X- _ O
illness -X- _ O
, -X- _ O
but -X- _ O
it -X- _ O
has -X- _ O
now -X- _ O
been -X- _ O
established -X- _ O
as -X- _ O
the -X- _ O
cause -X- _ O
of -X- _ O
severe -X- _ O
clinical -X- _ O
manifestations -X- _ O
, -X- _ O
including -X- _ O
fetal -X- _ O
anomalies -X- _ O
, -X- _ O
neurological -X- _ O
problems -X- _ O
, -X- _ O
and -X- _ O
autoimmune -X- _ O
disorders. -X- _ O
Infection -X- _ O
during -X- _ O
pregnancy -X- _ O
can -X- _ O
cause -X- _ O
congenital -X- _ O
brain -X- _ O
abnormalities -X- _ O
, -X- _ O
including -X- _ O
microcephaly -X- _ O
and -X- _ O
neurological -X- _ O
degeneration -X- _ O
, -X- _ O
and -X- _ O
in -X- _ O
other -X- _ O
cases -X- _ O
, -X- _ O
Guillain-Barré -X- _ O
syndrome -X- _ O
, -X- _ O
making -X- _ O
infections -X- _ O
with -X- _ O
ZIKV -X- _ O
a -X- _ O
substantial -X- _ O
public -X- _ O
health -X- _ O
concern. -X- _ O
Genomic -X- _ O
and -X- _ O
molecular -X- _ O
investigations -X- _ O
are -X- _ O
underway -X- _ O
to -X- _ O
investigate -X- _ O
ZIKV -X- _ B-Patient
pathology -X- _ O
and -X- _ O
its -X- _ O
recent -X- _ O
enhanced -X- _ O
pathogenicity -X- _ O
, -X- _ O
as -X- _ O
well -X- _ O
as -X- _ O
to -X- _ O
design -X- _ O
safe -X- _ O
and -X- _ O
potent -X- _ O
vaccines -X- _ O
, -X- _ O
drugs -X- _ O
, -X- _ O
and -X- _ O
therapeutics. -X- _ O
This -X- _ O
review -X- _ O
describes -X- _ O
progress -X- _ O
in -X- _ O
the -X- _ O
design -X- _ O
and -X- _ O
development -X- _ O
of -X- _ O
various -X- _ B-Intervention
anti-ZIKV -X- _ I-Intervention
therapeutics -X- _ I-Intervention
, -X- _ I-Intervention
including -X- _ I-Intervention
drugs -X- _ I-Intervention
targeting -X- _ I-Intervention
virus -X- _ I-Intervention
entry -X- _ I-Intervention
into -X- _ I-Intervention
cells -X- _ I-Intervention
and -X- _ I-Intervention
the -X- _ I-Intervention
helicase -X- _ I-Intervention
protein -X- _ I-Intervention
, -X- _ I-Intervention
nucleosides -X- _ I-Intervention
, -X- _ I-Intervention
inhibitors -X- _ I-Intervention
of -X- _ I-Intervention
NS3 -X- _ I-Intervention
protein -X- _ I-Intervention
, -X- _ I-Intervention
small -X- _ I-Intervention
molecules -X- _ I-Intervention
, -X- _ I-Intervention
methyltransferase -X- _ I-Intervention
inhibitors -X- _ I-Intervention
, -X- _ I-Intervention
interferons -X- _ I-Intervention
, -X- _ I-Intervention
repurposed -X- _ I-Intervention
drugs -X- _ I-Intervention
, -X- _ I-Intervention
drugs -X- _ I-Intervention
designed -X- _ I-Intervention
with -X- _ I-Intervention
the -X- _ I-Intervention
aid -X- _ I-Intervention
of -X- _ I-Intervention
computers -X- _ I-Intervention
, -X- _ I-Intervention
neutralizing -X- _ I-Intervention
antibodies -X- _ I-Intervention
, -X- _ I-Intervention
convalescent -X- _ I-Intervention
serum -X- _ I-Intervention
, -X- _ I-Intervention
antibodies -X- _ I-Intervention
that -X- _ I-Intervention
limit -X- _ I-Intervention
antibody-dependent -X- _ I-Intervention
enhancement -X- _ I-Intervention
, -X- _ I-Intervention
and -X- _ I-Intervention
herbal -X- _ I-Intervention
medicines. -X- _ I-Intervention
Additionally -X- _ O
, -X- _ O
covalent -X- _ B-Intervention
inhibitors -X- _ I-Intervention
of -X- _ I-Intervention
viral -X- _ I-Intervention
protein -X- _ I-Intervention
expression -X- _ I-Intervention
and -X- _ I-Intervention
anti-Toll-like -X- _ I-Intervention
receptor -X- _ I-Intervention
molecules -X- _ I-Intervention
are -X- _ O
discussed. -X- _ O
To -X- _ O
counter -X- _ O
ZIKV-associated -X- _ O
disease -X- _ O
, -X- _ O
we -X- _ O
need -X- _ O
to -X- _ O
make -X- _ O
rapid -X- _ O
progress -X- _ O
in -X- _ O
developing -X- _ O
novel -X- _ O
therapies -X- _ O
that -X- _ O
work -X- _ O
effectually -X- _ O
to -X- _ O
inhibit -X- _ O
ZIKV -X- _ B-Patient
. -X- _ O

